DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING RELATED SUBSTANCES OF ATENOLOL AND NITRENDIPINE BY RP-HPLC

THULASEEDHAR ALUMURI; NAMBURI L. A. AMARABABU; ARAVİND KURNOOL; PHANI RAJA KANUPARTHY; KARUNASREE MERUGU

doi:10.22159/ijap.2022v14i4.44531

Authors

THULASEEDHAR ALUMURI Department of Chemistry, GITAM (Deemed to be University), Bengaluru 560034, Karnataka, India
NAMBURI L. A. AMARABABU New Generation Materials Lab (NGML), Department of Science and Humanities, Vignan’s Foundation for Science Technology and Research University (VFSTR) (Deemed to be University), Vadlamudi, Guntur-522 213, Andhra Pradesh, India
ARAVİND KURNOOL Department of Chemistry, Osmania University, Hyderabad 500007, Telangana, India
PHANI RAJA KANUPARTHY Department of Chemistry, GITAM (Deemed to be University), Hyderabad 502329, Telangana, India
KARUNASREE MERUGU Department of Chemistry, GITAM (Deemed to be University), Bengaluru 560034, Karnataka, India

DOI:

https://doi.org/10.22159/ijap.2022v14i4.44531

Keywords:

Atenolol, Nitrendipine, Related impurities, HPLC, Validation

Abstract

Objective: A validated stability-indicating RP-HPLC method for Atenolol and Nitrendipine was developed by separating its related impurities.

Methods: By using Waters HPLC e-2695 quaternary pump with a PDA detector of 2998 instrument, the chromatographic separation of Atenolol, Nitrendipine and its related impurities was achieved on the column of Agilent eclipse C₁₈ (150x4.6 mm, 3.5 µ) using gradient elution with a buffer containing 0.1percent formic acid and acetonitrile as a mobile phase with a flow rate of 1 ml/min at ambient temperature. A detector wavelength of 218 nm utilizing the PDA detector was given in the instrumental settings. The linearity was studied between the concentration range of 6.25-37.5 µg/ml of Atenolol, 0.75-4.5 µg/ml each of Atenolol imp-A, imp-B and 5-30 µg/ml of Nitrendipine, 0.5-3 µg/ml each of Nitrendipine imp-1, imp-2 were injected with a run time of 40 min. Validation of the proposed method was carried out according to an International Conference on Harmonization (ICH) guidelines.

Results: LOD and LOQ for the Atenolol and its impurities were established with respect to test concentration. The plotted calibration curves were linear with a regression coefficient of R²>0.999, indicating that the linearity was with in the limit. As a part of method validation the parameters like specificity, linearity, accuracy, ruggedness, robustness were determined and the results were found to be within the allowable limit.

Conclusion: The method developed was found to be applicable to routine analysis and to be used for the measurement of active pharmaceutical ingredients (i. e, Atenolol, Nitrendipine and their related impurities). Since there is no HPLC method reported in the literature for the estimation of Atenolol, Nitrendipine and their related impurities, there is a need to develop quantitative methods under different conditions to achieve improvement in specificity selectivity etc.

Downloads

Download data is not yet available.

References

Larochelle P, Tobe SW, Lacourcière Y. β-blockers in hypertension: studies and meta-analyses over the years. Can J Cardiol. 2014;30(5)Suppl:S16-22. doi: 10.1016/j.cjca.2014.02.012, PMID 24750978.

Zipursky JS, Macdonald EM, Luo J, Gomes T, Mamdani MM, Paterson JM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network. Lipophilic β-blockers and suicide in the elderly. J Clin Psychopharmacol. 2017;37(3):381-4. doi: 10.1097/JCP.0000000000000695, PMID 28338548.

Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386(9995):801-12. doi: 10.1016/S0140-6736(14)61468-9, PMID 25832858.

Wertli MM, Ruchti KB, Steurer J, Held U. Diagnostic indicators of non-cardiovascular chest pain: a systematic review and meta-analysis. BMC Med. 2013;11:239. doi: 10.1186/1741-7015-11-239, PMID 24207111.

Tomiyama H, Yamashina A. Beta-blockers in the management of hypertension and/or chronic kidney disease. Int J Hypertens. 2014;2014:1-7. doi: 10.1155/2014/919256, PMID 919256.

DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D’Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O’Keefe JH. β-blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015;2(1):e000230. doi: 10.1136/openhrt-2014-000230, PMID 25821584.

McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877-89. doi: 10.1016/S0140-6736(05)66621-4, PMID 15924986.

Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de Lemos JA, Berry JD. Dose-response relationship between physical activity and risk of heart failure: A meta-analysis. Circulation. 2015;132(19):1786-94. doi: 10.1161/circulationaha.115.015853, PMID 26438781.

Chu ECP, Chin WL, Bhaumik A. Cervicogenic dizziness. Oxf Med Case Reports. 2019;2019(11):476-8. doi: 10.1093/omcr/omz115, PMID 31844531.

Shiber JR, Santana J. Dyspnea. Med Clin North Am. 2006;90(3):453-79. doi: 10.1016/j.mcna.2005.11.006, PMID 16473100.

Torres M, Moayedi S. Evaluation of the acutely dyspneic elderly patient. Clin Geriatr Med. 2007;23(2):307-25. doi: 10.1016/j.cger.2007.01.007, PMID 17462519.

Hu LA, Chen W, Martin NP, Whalen EJ, Premont RT, Lefkowitz RJ. GIPC interacts with the beta1-adrenergic receptor and regulates beta1-adrenergic receptor-mediated ERK activation. J Biol Chem. 2003;278(28):26295-301. doi: 10.1074/jbc.M212352200, PMID 12724327.

Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am. 2014;32(2):277-92. doi: 10.1016/j.emc.2013.12.001, PMID 24766932.

Tobin KJ. Stable angina pectoris: what does the current clinical evidence tell us? J Am Osteopath Assoc. 2010;110(7):364-70. PMID 20693568.

Titterington JS, Hung OY, Wenger NK. Microvascular angina: an update on diagnosis and treatment. Future Cardiol. 2015;11(2):229-42. doi: 10.2217/fca.14.79, PMID 25760881.

El-Sherif N, Turitto G, Boutjdir M. Acquired long QT syndrome and electrophysiology of torsade de points. Arrhythm Electrophysiol Rev. 2019;8(2):122-30. doi: 10.15420/aer.2019.8.3, PMID 31114687.

Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, Perier MC, Marijon E, Vernerey D, Empana JP, Jouven X. Main air pollutants and myocardial infarction: a systematic review and meta-analysis. JAMA. 2012;307(7):713-21. doi: 10.1001/jama.2012.126, PMID 22337682.

Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;(8):CD011054. doi: 10.1002/14651858.CD011054.pub2, PMID 26310586.

Al-Zaiti SS, Magdic KS. Paroxysmal supraventricular tachycardia: pathophysiology, diagnosis, and management. Crit Care Nurs Clin North Am. 2016;28(3):309-16. doi: 10.1016/j.cnc.2016.04.005, PMID 27484659.

Baldzizhar A, Manuylova E, Marchenko R, Kryvalap Y, Carey MG. Ventricular tachycardias: characteristics and management. Crit Care Nurs Clin North Am. 2016;28(3):317-29. doi: 10.1016/j.cnc.2016.04.004, PMID 27484660.

Farrell JB, Deshmukh A, Baghaie AA. Low testosterone and the association with type 2 diabetes. Diabetes Educ. 2008;34(5):799-806. doi: 10.1177/0145721708323100, PMID 18832284.

Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S, LIFE study group. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens. 2002;20(9):1879-86. doi: 10.1097/00004872-200209000-00035, PMID 12195132.

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201-7. doi: 10.1016/S0140-6736(07)60108-1, PMID 17240286.

Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545-53. doi: 10.1016/S0140-6736(05)67573-3, PMID 16257341.

Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737-42. doi: 10.1503/cmaj.060110, PMID 16754904.

Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903-7. doi: 10.1001/jama.279.23.1903, PMID 9634263.

Trouve R, Nahas G. Nitrendipine: an antidote to cardiac and lethal toxicity of cocaine. Proc Soc Exp Biol Med. 1986;183(3):392-7. doi: 10.3181/00379727-183-3-rc1, PMID 3797422.

Siddiqui MA, Plosker GL. Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension. Drugs. 2004;64(10):1135-48. doi: 10.2165/00003495-200464100-00009, PMID 15139792.

Shivaraj Gowda S, Prakash B Desai PB, Vinayak V Hull VV, Avinash AK Math AAK, Sonal N Vernekar SN, Shruthi S Kulkarni SS. A review on laboratory liver function tests. The Pan African Medical Journal. 2009;3:17. PMID 21532726.

Geyer PE, Kulak NA, Pichler G, Holdt LM, Teupser D, Mann M. Plasma proteome profiling to assess human health and disease. Cell Syst. 2016;2(3):185-95. doi: 10.1016/j.cels.2016.02.015, PMID 27135364.

Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol Rev. 2013;65(2):578-640. doi: 10.1124/pr.111.005439, PMID 23406671.

Indik Julia H, Indik JH. When palpitations worsen. Am J Med. 2010;123(6):517-9. doi: 10.1016/j.amjmed.2010.01.012, PMID 20569756.

Cijo M Xavier, Kanakapura Basavaiah. RP-UPLC development and validation of metformin hydrochloride in pure drug and pharmaceutical formulations. World Journal Pharmacy and Pharmaceutical Sciences. 2015;4:1649-68.

Shalini K, Ilango K. Development, evaluation and RP-HPLC method for simultaneous estimation of quercetin, ellagic acid and kaempferol in a poly herbal formulation. Int J Appl Pharm. 2021;13:183-92.

Sri Girija K, Bikshal Babu K, Venkateswara Rao A, Girija KS, Kasimala BB, Anna VR. A new high-performance liquid chromatography method for the separation and simultaneous quantification of eptifibatide and its impurities in pharmaceutical injection formulation. Int J App Pharm. 2021;13:165-72. doi: 10.22159/ijap.2021v13i2.39895.

VLN Balaji Gupta VLN T, Venkateswara Rao B, Kishore Bbabu B. RP-HPLC (stability-indicating) based assay method for the simultaneous estimation of Doravirine, tenofovir disoproxil fumarate and lamivudine. Int J Appl Pharm. 2021;13:153-9.

Murali Krishnam Raju P, Venkata Narayana B, Shyamala P, Srinivasu K, Raju HSN D. A validated RP-HPLC method for impurity profiling of sodium nitroprusside in an injection dosage form. Int J Appl Pharm. 2021;13:160-9.

Sanathoiba Singha L, Srinivasa Rao T. Development and validation of an RP-HPLC method for the determination of ulipristal acetate in the pharmaceutical dosage form. Asian J Pharm Clin Res. 2021;14:83-9.

Eluru A, Surendra Babu K. A study of method development, validation and forced degradation for simultaneous quantification of povidone-iodine and ornidazole in bulk and pharmaceutical dosage form by using RP-HPLC. IJPSR. 2021;12:1217-22.

Malathi S, Devakumar D. Development and validation of RP-HPLC method for the estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form and plasma. Int J Pharm Pharm Sci. 2021;13:61-6.

International Conference on Harmonization (ICH). Harmonized tripartite guideline validation of analytical procedures: text and methodology Q2. Vol. R1. Geneva: IFPMA. Switzerland; 2005.

Ravichandran V, Shalini S, Sundaram KM, Rajak H. Validation of analytical methods-strategies and importance. Int J Pharm Pharm Sci. 2010;2:18-22.

Gunturu Raviteja, Kantipudi Rambabu. A study of development and validation of a method for simultaneous estimation of cidofovir and famciclovir using RP-HPLC. IJRPS 2020;11(4):7878-84. doi: 10.26452/ijrps.v11i4.4673.

Vijayakumari M, Reddy Ch B. Stability indicating validated hplc method for the determination of zanubrutinib in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res. 2020;13:159-62.

Mohinish Sahai M, Devanna N. Validated stability-indicating HPLC approach for quantifying tricholine citrate and cyproheptadine simultaneously in syrup forms. Int J App Pharm. 2021;13:207-13. doi: 10.22159/ijap.2021v13i3.40871.

Raziq A, Syed Umer Jan. Relative comparison of stability and degradation of methylcobalamine tablets of different brands at different storage settings. Int J Appl Pharm. 2021;13:171-5.

Rajakumari R, Sreenivasa Rao S. Stress degradation studies and development of a validated RP-HPLC method for determination of tiagabine in the presence of its degradation products. Int J Pharm Pharm Sci. 2016;8:230-6.

Charu Pandya P, Sadhana Rajput J. Development and validation of stability indicating method RP-HPLC method of acotiamide. Int J Pharm Pharm Sci. 2018;10:1-8.

Athavia BA, Dedania ZR, Dedania RR, Swamy SMV, Prajapati CB. Stability indicating hplc method for determination of vilazodone hydrochloride. Int J Curr Pharm Sci 2017;9(4). doi: 10.22159/ijcpr.2017v9i4.20975.